Anna Brown, PharmD, BCOP

Clinical Pharmacist Specialist - Ambulatory Hematology
Residency Program Coordinator- PGY2 Oncology
RAC Mentor: PGY1 Pharmacy
Adjunct Clinical Instructor
Rotation(s) Offered: Ambulatory Hematology, Symptom Management Clinic


My clinical practice is in ambulatory hematology where I participate in the multidisciplinary team taking care of patients with hematologic malignancies such a leukemia, lymphoma and myeloma as well as patients with benign hematologic conditions.

Pharmacy School Attended: University of Michigan (2008)

Additional Training:

  • PGY1 Pharmacy Practice Residency, University of Michigan, Ann Arbor, MI (2009)
  • PGY2 Oncology Residency, University of Michigan, Ann Arbor, MI (2010)
  • Integrative Oncology Scholar – in training, University of Michigan, Ann Arbor, MI (2020-2021)

Areas of Interest

  • Hematologic malignancies and benign hematology
  • Complementary and alternative medicine
  • Oncology quality initiatives
  • Scope of the oncology pharmacist
  • Continuous process improvement

Honors & Awards

    • Michigan Society of Health-System Pharmacist (MSHP) President’s AwardTheme: Achieving Patient Care OutcomesRogel Cancer Center Ambulatory Oncology Pharmacy Services

      Members: Lydia Benitez-Colon, Anna Brown, Catherine Christen, David Frame, Shannon Hough, Shawna Kraft, Rachel McDevitt, Victoria Nachar

Published Articles or Reviews

  • The feasibility of virtual toxicity assessments in lymphoma patients receiving immunochemotherapy. Runge JS, Brown AB, Phillips TJ, Kaminski MS, Carty SA, Wilcox RA. Abstract submission to American Society of Hematology Annual Meeting 2020.
  • Considerations for use of hematopoetic growth factors in cancer patients related to the COVID-19 Pandemic. Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Koth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS.  Accepted for publication in JNCCN.
  • Chemotherapy remote care monitoring program (CRCMP): Integration of an SMS test patient-reported outcome (PRO) in the electronic health record (EHR) to identify patients needing pharmacist intervention for chemotherapy-induced nausea and vomiting (CINV). Hough S, McDevitt R, Nachar V, Kraft S, Brown A, Christen C, Walters B, Smerage J. J Clin Oncol 38:2020 (suppl; abstr 2001). DOI: 10.1200/JCO.2020.38.15_suppl.2001.  (Selected for Oral Abstract Session as part of 2020 ASCO Virtual Scientific Program, Submitted to JCO Oncology Practice for publication)
  • Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. Reid JH, Marini BL, Nachar VR, Brown AM, Devata S, Perissinotti AJ. Crit Rev Oncol Hematol. 2020 Feb 13. doi: 10.1016/j.critrevonc.2020.102897  [Epub ahead of print]
  • Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. Weis TM, Marini BL, Nachar VR, Brown A, Phillips TJ, Brown J, Wilcox RA, Kaminski M, Devata S, Perissinotti, AJ. Leuk Lymphoma. 2020;61(5):1126-1132.
  • NCCN guideline insights: hematopoietic growth factors, version 1.2020.  Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Dinner S, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Miller R, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Rosovsky R, Roy V, Rugo HS, Shayani S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Burns J, Keller J, Pluchino LA. J Natl Compr Canc Netw. 2020;18(1):12-22.
  • Sickle Cell Anemia. Anna Brown. PharmacotherapyFirst: A Multimedia Learning Resource. 2019 Nov 19. doi: 10.21019/pharmacotherapyfirst.sicklecell_overview. [Epub]
  • Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, Campagnaro E, Nachar VR. Leuk Lymphoma. 2020;61(3):691-698.
  • Dosing vincristine in dose-adjusted EPOCH-R: to cap or not to cap? Weis TM, Perissinotti AJ, Nachar VR, Brown AB, Phillips TJ, Marini BL. J Clin Oncol. 2019 Nov 1;37(31):2952.
  • Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma. Neumann DR, Marini BL, Phillips TJ, Wilcox RA, Mayer TL, Brown A, Perissinotti AJ.  Leuk Lymphoma 2018;59(7):1596-1605